Ablating short-segment Barrett esophagus: What’s your weapon of choice?

August 7th, 2011

Ablating short-segment Barrett esophagus: What’s your weapon of choice?

The first cases of Barrett esophagus (BE) ablation in the late 1980s used YAG and Argon laser. Since then, a myriad of ablation techniques have been described, including multipolar electrocautery (MPEC), argon plasma coagulation (APC), cryotherapy, radiofrequency ablation (RFA), and endoscopic mucosal resection (EMR). Each technique has had its advocates, and some of the techniques appear to have certain advantages in certain types of BE: e.g., long segment, nodular, etc.

Most cases of BE are short segment, and most neoplastic cases do not have nodules or erosions. So the question I would like to see discussed is: In a patient with 1–2 cm of otherwise featureless flat but neoplastic BE:

What ablation technique would you use, and what do you feel makes this technique advantageous?

What would be your second option, and when would you employ it?

Do you use more than one technique, and, if so, which ones do you use and why?

What are the most common complications you see with BE ablation?

What is your overall success at complete BE elimination?

We look forward to your comments.

Categories: Patient care
Tags: Barrett esophagus

You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

A Rare-in-Common Paradigm for Precision Genomic Medicine October 23, 2025

Precision medicine tailors clinical management strategies for treatment and prevention in light of each person’s genetic makeup, history of environmental exposures, and lifestyle. More specifically, precision medicine is about making correct, actionable diagnoses and offering appropriate, patient-specific treatment. Genomics has contributed to precision medicine, especially in the areas of rare...

Common Diseases in Clinical Cohorts — Not Always What They Seem October 23, 2025

Analyses of U.K. Biobank and clinical cohorts show that rare genetic diseases can be misdiagnosed as common diseases, which may have implications for clinical trials as well as for diagnosis and treatment.

BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease October 16, 2025

Teclistamab, a T-cell engager targeting B-cell maturation antigen, showed promise as a rescue therapy in 10 patients with refractory autoimmune diseases and led to clinical and serologic improvements in most patients.

Gut Check on Gastroenterology Archive

Gut Check on Gastroenterology, an NEJM Journal Watch blog focusing on issues in clinical gastroenterology, was active from 2008 to 2014. This archive contains all posts and discussions from Gut Check’s history.

August 7th, 2011